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 TEACHING LECTURE: 
  
SP-0613   
Target volume definition in upper GI malignancies 
K. Haustermans1 
1University Hospital Gasthuisberg - Radiation Oncology, Radiation 
Oncology, Leuven, Belgium  
  
This teaching lecture will focus on esophageal and gastric cancer. It 
remains a challenge to treat these patients outside a context of 
clinical trials. 
Different published delineation guidelines will be discussed and 
compared in esophageal and gastric cancer. The role of imaging 
modalities such as endoscopy, endoscopic ultrasound, CT scan, FDG-
PET-CT in the delineation process and during (chemo) radiotherapy 
will be highlighted. 
Whether squamous cell carcinoma and adenocarcinoma of the 
esophagus can be regarded as one tumor entity remains unclear. The 
same holds true for adenocarcinomas of the GE junction and the 
stomach.  
Organs at risk and dose constraints will be considered. The challenge 
of organ motion and tumor shrinkage during a course of (preoperative) 
chemoradiation will be discussed. 
Learning objectives: 
1. To understand the impact on target definition and delineation when 
comparing preoperative versus postoperative chemoradiation 
2. To understand the impact of different imaging modalities on the 
delineation process 
3. To understand the impact of organ motion during treatment 
4. To understand the impact of tumor shrinkage  during treatment 
 
SP-0614   
Clinical audit 
P. Scalliet1 
1UCL Cliniques Univ. St.Luc, radiation oncology, Brussels, Belgium  
 
As part of a comprehensive approach to quality assurance in the 
treatment of cancer by radiation, an independent external audit (peer 
review) is important to ensure adequate quality of practice and 
delivery of treatment [1]. Historically, clinical audits in radiotherapy 
have been promoted by IAEA, after the development of a specific 
methodology in which ESTRO members played an active role. It is 
available on the IAEA website under the name QUATRO (quality 
assurance team for radiation oncology). 
To capture the actual level of competence of a department, the audit 
addresses simultaneously the issues of equipment, infrastructure and 
operation of clinical practice. A major part of the audit is patient 
oriented. It is carried out by experts inthe 3 main disciplines: RTT, 
medical physics and radiation oncology. 
A clinical audit is not a pass or fail test; it is a process by which a 
comprehensive quality management system is measured against pre-
defined standards or codes of good practice. Its result is a series of 
recommendations that could fall in 3 categories: (1) urgent corrective 
actions needed (with or without consecutive re-audit), (2) corrective 
actions to be implemented in the future without urgent need, and (3) 
no specific recommendations. The latter category implies that the 
department runs at an appropriate level of qualityand safety. This 
does not mean that quality and safety have been achieved, as both 
should be permanently developed and updated, but that the 
department has adynamic and organised management system that 
constantly checks upon their appropriateness.  
An appropriate management system is a system with an organized 
prospective and retrospective quality and safety monitoring, a system 
that learns from its mistakes (implying that mistakes are actively 
recorded and analysed), and a system reactive to innovation 
(proactive safety management through FMEA). Indeed, quality is not a 
goal, quality is away. 
Well over 50 hospitals have been already audited in Europe (Central 
and Eastern) and, in some countries, the clinical audits are already a 
legal requirement, in compliance with EURATOM directives. 
Morerecently, Belgium, through its Federal College of Radiotherapy, 
has started a program for systematic auditing of radiotherapy 
departments, drawing upon the IAEA experience and with the help of 
some of its experts. Ten hospitals have already been audited (out of 
25) and results will be presented at theconference. 
[1]Comprehensive Audits of Radiotherapy Practice: a tool for Quality 
Improvement.IAEA, Vienna, 2007 (http://www.iaea.org/books). 
 
 
 
 
SP-0615  
Collective cancer invasion: an integrin-dependent, normoxic 
radioresistance niche 
P. Friedl1 
1Radboud University Nijmegen Medical Center, Department of Cell 
Biology, Nijmegen, The Netherlands  
 
The tumor microenvironment contributes to cancer invasion, growth 
and survival and thereby impacts tumor responses to therapy. We here 
developed an intravital infrared multiphoton imaging model for the 
multi-parameter visualization of collective cancer cell invasion, 
guidance by the tumor stroma, and short- and long-term resistance to 
experimental anti-cancer therapy. The data show for orthotopic 
fibrosarcoma and melanoma xenografts deep invasive growth driven 
by proliferation concurrent with collective invasion of multicellular 
strands along the normoxic perivascular stroma. Invasion was fast (up 
to 200 µm per day), non-destructive and independent of β1 and β3 
integrins. Despite normoxia, perivascular invasion strands were 
resistant to high-dose hypofractionated irradiation which otherwise 
was sufficient to induce regression of the tumor main mass. This 
invasion-associated radioresistance was sensitive to the simultaneous 
inhibition of β1 and β3 integrins by RNA interference or combined 
anti-β1/aV integrin antibody treatment caused by proliferation arrest, 
anoikis induction ablating both tumor lesion and invasion strands. In 
conclusion, collective invasion is an important invasion mode in solid 
tumors into a microenvironmentally priviledged survival niche which 
conveys radioresistance by integrin-dependent signals. These findings 
show how “dynamic in vivo cell biology” identifies a key role for 
integrin-mediated signaling in mediating cross-talk (reciprocity) 
between the peri-tumor stroma and the tumor cells to mediate 
altered biology and response to therapy (plasticity). 
 
SP-0616   
How will the new International Basic Safety Standards affect the 
medical physics practice? 
A. Meghzifene1, J. Le Heron2 
1IAEA - International Atomic Energy Agency, Human Health - Nuclear 
Science & Applications, Vienna, Austria  
2IAEA - International Atomic Energy Agency, Radiation Transport and 
Waste Safety - Nuclear Safety and Security, Vienna, Austria  
  
This paper presents the main elements of the new Radiation 
Protection and Safety of Radiation Sources: International Basic Safety 
Standards (the BSS) as it relates to the field of medical radiation 
physics and highlights the potential benefits for the professionals 
working in this field.  
The BSS is developed by the IAEA and the co-sponsoring organizations 
through an open and transparent process including inputs from IAEA 
Member States and international organizations such as the 
International Organization for Medical Physics (IOMP). The BSS 
contains a chapter giving the general requirements covering all 
practices, including uses of radiation in medicine, research and 
teaching, and also emergency exposure situations and existing 
exposure situations. This is followed by three chapters giving detailed 
requirements for each of the three exposure situations, one of which 
addresses medical exposure. The section on medical exposure covers 
the responsibilities of those involved including medical physicists, the 
justification of medical exposures, the optimization of protection 
covering design and operational considerations, calibration, dosimetry 
of patients, diagnostic reference levels and quality assurance, the 
release of patients after radionuclide therapy, the investigation of 
unintended and accidental medical exposure, and records. The BSS 
plays an important role in many countries; it is often taken as a 
template for national regulations, and it is mandatory for those 
countries receiving technical cooperation assistance from the IAEA.  
In the field of medical radiation physics, significant changes have 
been introduced in the new BSS. First, the medical physicist is 
identified in the new BSS as one of the key professionals, together 
with the radiological medical practitioner and technologist/ 
radiographer, with responsibilities for quality assurance and patient 
radiation protection. Training and clinical competence requirements 
for medical physics practice are identified in the BSS. Medical 
physicists can practice only if they are specialized in the appropriate 
area, such as radiotherapy,nuclear medicine, diagnostic radiology or 
image guided interventional procedures. The details of the 
specialization have to be defined at the national level by the relevant 
professional body, health authority or other appropriate organization. 
According to the BSS, for therapeutic uses of radiation, the 
requirements for calibration, dosimetry and QA, including the 
acceptance and commissioning of medical radiological equipment, 
need to be fulfilled by or under the supervision of a medical physicist. 
For diagnostic uses and image-guided interventional procedures, the 
requirements for imaging, calibration, dosimetry and QA, including 
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the acceptance and commissioning of medical radiological equipment, 
need to be fulfilled by or under the oversightof or with the 
documented advice of a medical physicist. The degree of involvement 
of the medical physicist in diagnostic uses and image-guided 
interventional procedures is determined by the complexity of the 
radiological procedures and the associated radiation risks.  
In conclusion, the new BSS identifies the medical physicist as a key 
professional with a specialized training, skills and competence in 
clinical medical physics and radiation protection. The medical 
physicist has significant responsibilities in the many activities that are 
needed to successfully implement the quality assurance programme 
and radiation protection principle of optimization for medical 
exposure in a given hospital or medical centre. If these new BSS 
requirements are effectively implemented, they will help pave the 
way for a full recognition of the medical physicist as a health care 
professional alongside other professionals working in the medical 
field. 
 
SP-0617   
An overview of imaging techniques for patient positioning 
R. Moeckli1 
1Institute of Radiation Physics, Lausanne University Hospital, 
Lausanne, Switzerland  
 
Purpose/Objective:  Imaging for patient positioning is part of the 
image guided radiation therapy (IGRT) workflow and is routinely used 
in clinical practice. The primary objective is to check and correct the 
patient position with such an improved day to day reproducibility that 
dose delivery to the target volume and organs at risks is the most 
similar to the planned one. This can be accomplished by plenty of 
imaging techniques based on kV, MV or ultrasound imaging and made 
available by companies in various mechanical configurations. The 
objective of this teaching lecture is to provide an overview of the 
different techniques used and to evaluate their respective pros and 
cons. 
Materials/Methods: A review of literature is presented from the 
simplest two dimensional imaging techniques to the most advanced 
ones capable of imaging the movement of the patient in four 
dimensions (4D). Special focus is presented on high precision 
irradiation techniques such as stereotactic radiosurgery, where 
treatment outcome is the most dependent on accurate patient 
positioning.  
Results: Globally, the performance of the most advanced imaging 
techniques allows us to position the patient and the target volume 
within millimeters and even under 1 mm for parts of the body which 
can be rigidly immobilized. Also taking into account target volume 
movements with 4D imaging techniques prior to treatment, e.g. for 
lung treatments, allow us to reduce the irradiated volume and 
therefore potentially reduce toxicity. The great improvement of 
imaging techniques in recent years raises then the question of the 
interest of frameless high precision irradiation techniques, because 
these techniques, based on imaging without invasive frame 
contention, are definitely providing equivalent degree of accuracy in 
patient positioning.  
Conclusions: IGRT techniques for patient positioning are widespread 
in clinical practice. Recent improvements allow us to position the 
patient and the target volume within 1mm accuracy. Most advanced 
techniques even take into account target movement by 4D imaging of 
patient positioning. Stereotactic high precision irradiation based on 
frameless imaging also challenges the usual invasive frame-based 
technique for patient positioning precision. 
 
SP-0618   
Modern brachytherapy: The technical opportunities  
M.A. Moerland1 
1University Medical Center Utrecht, Department of Radiation 
Oncology, Utrecht, The Netherlands  
 
The strength of brachytherapy (BT) is that the radiation sources are 
inside or in the vicinity of the target volume and that they generally 
move with the target. The target dose is high and due to the inverse 
square law the dose to the surrounding normal tissue (organs at risk) 
can be reduced considerably. Therefore, BT has gained a definite 
place in the treatment of patients with gynaecological, head and 
neck, breast and prostate tumours.  
Brachytherapy has been applied since 1901, a few years after the 
discovery of x-rays and radium. Important developments in the 
medical application of radionuclides were the dosimetry systems 
(Stockholm, Paris, Manchester), the discovery of artificial 
radioactivity ( 60Co,137Cs, 198Au, 192Ir) and the development of 
remote afterloading devices. 
The field of BT continues to develop and the introduction of new 
technology brings new questions and challenges [1]: 
new afterloading devices, new dose calculation algorithms, 3D image 
based dose planning, new applicators,  application of knowledge of 
radiobiology to optimize treatment schedules, robotic brachytherapy 
for prostate seed implant, electronic brachytherapy sources and in 
vivo dosimetry. 
 A major improvement of BT may be expected from the use of 3D 
imaging, especially magnetic resonance imaging (MRI).  MRI does not 
completely replace clinical investigation and other imaging 
modalities, but its superior soft tissue contrast often helps to better 
define tumor stage, target volume extension and organs at risk at 
time of diagnosis, at time of BT and for treatmentplanning purposes.  
During the last years we see a development towards MR guided BT in 
different tumor sites(gynaecology, prostate). This presentation will 
focus on technology for MRI guided BT and how anatomical and 
functional MRI optimize and individualize BT approaches. 
1. Venselaar JL, Baltas D, Meigooni AS, Hoskin PJ (editors), 
Comprehensive Brachytherapy; Physical and Clinical Aspects, CRC 
Press, 2012. 
  
 JOINT SYMPOSIUM: ESTRO-JASTRO: ESOPHAGEAL 
CANCER: STANDARD OF PRACTICE COMPARISON  
  
SP-0619   
Chemoradiotherapy for early-stage esophageal cancer - Japanese 
perspective 
K. Nemoto1 
1Yamagata University, Radiaiton Oncology, Yamagata, Japan  
  
Superficial esophageal cancer (SEC) is defined as esophageal cancer 
limited to the submucosal layer and includes mucosal and submucosal 
cancer. Based on the criteria of the Japanese Society for Esophageal 
Disease, Mucosal and submucosal cancer is classified according to 
location: epithelial layer (m1); proper mucosal layer (m2); muscularis 
mucosa (m3); upper third of the submucosal level (sm1); middle third 
of the submucosal layer (sm2); and the lower third of the submucosal 
level (sm3). Irrespective of the treatment method, the depth of 
invasion is one of the most important prognostic factors of SEC 
because lymph node metastasis markedly increases in lesions 
infiltrating the lamina muscularis mucosa (m3).  
The best management of small m1 and m2 esophageal cancer is 
generally endoscopic resection (ER). For m3-sm3 SEC, extensive lymph 
node dissection has been the most popular choice of 
treatment.However, after introduction of chemoradiation therapy, 
good treatment outcomes which are comparable with those of surgery 
have been reported. In a Japanese phase II study of CRT for T1 
esophageal carcinoma (JCOG 9704), 4 and 5 year overall survival rates 
were 80.5% and 76.5%, respectively. In our prospective single 
institutional phase II study, local control rate, and overall survival 
rate was 80.3%, % 78.9and % respectively. From these data, we think 
CRT for early state esophageal carcinoma is one of the standard 
treatment methods.  
Combination of ER and CRT is another approach. If the depth of 
invasion reached to submucosa, surgery has been added to most 
patients because of the high rate of lymph node metastasis. However, 
treatment outcomes of post ER CRT to prevent lymph node recurrence 
seems to be excellent and this approach may become a standard 
treatment method for endoscopically resectable esophageal cancer.  
   
SP-0620   
Neoadjuvant chemoradiotherapy for early-stage esophageal cancer 
- European perspective  
J.J.B. van Lanschot1, A. van der Gaast2, M.C.C.M. Hulshof3 
1Erasmus Medical Center Rotterdam, Department of Surgery, 
Rotterdam, The Netherlands  
2Erasmus Medical Center Rotterdam, Department of Medical 
Oncology, Rotterdam, The Netherlands  
3Academic Medical Center at the University of Amsterdam, 
Department of Radiation Oncology, Amsterdam, The Netherlands  
  
Early-stage esophageal cancer can be defined as locally resectable 
disease ((1) Ever since, several important developments (including 
Barrett surveillance, improvement of clinical staging by e.g. PET 
scanning, centralization of care, refined perioperative therapy, and 
more radical surgical techniques) have improved short-term and long-
term outcome. However, 5-year survival after potentially curative 
surgical resection still rarely exceeds 35%. 
Many clinical trials have tested the potential value of neoadjuvant 
chemo- and/or radiotherapy to improve long-term outcome. In five 
randomized controlled trials (RCTs) the efficacy of neoadjuvant 
radiotherapy has been tested. A meta-analysis showed a non-
significant 4% increase of 5 year survival rate.(2) Nine RCTs have been 
